Targeting CD20 takes the backseat in CLL | Blood | American …
2019年3月7日 · In this issue of Blood, Burger and colleagues report results from a randomized phase 2 study combining rituximab and ibrutinib vs ibrutinib alone in high-risk, untreated, and …
Is there a role for anti-CD20 antibodies in CLL?
2021年12月10日 · Anti-CD20 monoclonal antibodies (mAbs) have revolutionized the treatment of chronic lymphocytic leukemia (CLL) by improving survival of patients with CLL in conjunction …
The regulation and function of CD20: an “enigma” of B-cell …
Rituximab improved progression-free survival and overall survival rates when added to chemotherapy in “mature” B-cell leukemias and lymphomas such as chronic lymphocytic …
CD20 Expression as a Possible Novel Prognostic Marker in CLL ...
To retrospectively study the influence of CD20 expression in CLL patients receiving anti-CD20 directed therapy on therapy response, we designed and evaluated a bead-based …
Circulating CD20 is detectable in the plasma of patients with …
2003年4月1日 · We demonstrate herein that significant levels of circulating CD20 (cCD20) can be detected in the plasma of patients with chronic lymphocytic leukemia (CLL) and that cCD20 …
Efficacy and safety of add-on anti-CD20 monoclonal antibody to …
2023年6月16日 · Our study demonstrates a significantly better outcome by adding anti-CD20 mAb to BTKi therapy in untreated or relapsed/refractory patients with CLL. The combined anti-CD20 …
Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia
Novel bioengineering techniques have helped in the development of anti-CD20 mAbs. One antibody, ofatumumab, was recently approved for the treatment of refractory CLL. A type II …
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL …
2023年7月28日 · Epcoritamab (GEN3013), an anti–CD3×CD20 bispecific antibody that recruits T-cell effector functions, has demonstrated potent clinical activity in patients with relapsed CD20 …
Starting Venetoclax Without Anti-CD20 Antibody Therapy - CLL …
2025年3月5日 · One way to do this is to start patients on anti-CD20 monoclonal antibody therapy (mAb), such as rituximab or obinutuzumab, prior to initiating venetoclax. However, because …
The predictive significance of CD20 expression in B-cell …
2011年4月12日 · CD20 expression in CLL is significantly lower than in most histological types of mature B-cell lymphomas in which it appears to be very comparable. Almost 25% of B-cell …